Ki67 in breast cancer: prognostic and predictive potential.

By R. Yerushalmi, R. Woods, P. Ravdin, M. Hayes, K. Gelmon. The Lancet Oncology, 2010

1,207 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, background): “analysis lacks reproducibility across laboratories and, therefore, cannot be consistently interpreted when performed in a broad range of laboratories.(71-75) IHC for Ki-67 is not recommended for broad clinical use to determine whether a patient should receive chemotherapy.”
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020, background): “patients, the intrinsic subtypes of the cancers, and application of therapies have been mixed or often not even reported (67).”
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry (2013, background): “However, to date no standard operating procedure (SOP) or generally accepted cut-off definition for Ki-67 exists [12, 13].”
Ki67 is a promising molecular target in the diagnosis of cancer (review). (2015, background): “as a prognostic marker over mitotic rate (97-100).”
An overview of triple-negative breast cancer (2016, background): “and in patients treated with antihormonal therapy [85], and some of its effect on the outcome appears to be unrelated to”